Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors

[1]  R. Schots,et al.  A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation , 2005, Leukemia.

[2]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[3]  F. Behm,et al.  Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors1 , 2005, The Journal of Immunology.

[4]  Eric Vivier,et al.  Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future , 2004, Nature Reviews Immunology.

[5]  C. Craddock,et al.  The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. , 2004, Blood.

[6]  R. Handgretinger,et al.  Determinants of Antileukemia Effects of Allogeneic NK Cells 1 , 2004, The Journal of Immunology.

[7]  F. Christiansen,et al.  KIR2DL4 (CD158d) Genotype Influences Expression and Function in NK Cells1 , 2003, The Journal of Immunology.

[8]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[9]  E. Ball,et al.  HLA-DRB1* intron-primed sequencing for haploid genotyping. , 2003, Clinical chemistry.

[10]  H. Trompeter,et al.  Crucial Role of DNA Methylation in Determination of Clonally Distributed Killer Cell Ig-like Receptor Expression Patterns in NK Cells1 , 2002, The Journal of Immunology.

[11]  Todd A Fehniger,et al.  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. , 2002, Blood.

[12]  P. Sun,et al.  A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. , 2002, Molecular immunology.

[13]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[14]  Heather G. Shilling,et al.  Allelic Polymorphism Synergizes with Variable Gene Content to Individualize Human KIR Genotype1 , 2002, The Journal of Immunology.

[15]  S. Ildstad,et al.  CD8+, αβ-TCR+, and γδ-TCR+ Cells in the Recipient Hematopoietic Environment Mediate Resistance to Engraftment of Allogeneic Donor Bone Marrow1 , 2002, The Journal of Immunology.

[16]  T. Braun,et al.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Cook,et al.  Resolution of cis-trans ambiguities between HLA-DRB1 alleles using single-strand conformation polymorphisms and sequencing. , 2001, Tissue antigens.

[18]  G. Vogelsang.  How I treat chronic graft-versus-host disease. , 2001, Blood.

[19]  William H. Carr,et al.  Different NK Cell Surface Phenotypes Defined by the DX9 Antibody Are Due to KIR3DL1 Gene Polymorphism1 , 2001, The Journal of Immunology.

[20]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[21]  R. Collins,et al.  Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. , 2000, Blood.

[22]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[23]  J. Strominger,et al.  Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. , 1998, Immunity.

[24]  Jun Wu,et al.  Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells , 1998, Nature.

[25]  J. Unkeless,et al.  Inhibitory receptors, ITIM sequences and phosphatases. , 1997, Current opinion in immunology.

[26]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[28]  P. Parham,et al.  The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor , 1995, The Journal of experimental medicine.

[29]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[30]  S. Sforzini,et al.  T cell clones expressing the natural killer cell‐related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function , 1994, European journal of immunology.

[31]  J. Hansen,et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.

[32]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[33]  Craig W. Reynolds,et al.  Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery , 1990 .

[34]  K. Anderson,et al.  Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. , 1986, Blood.